title: [AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab].
abstract: The treatment with immune checkpoint inhibitors has changed the entire natural history of advanced melanoma. In a recent study presented at the AACR Congress (New Orleans, April 16-20, 2016), immunotherapy with nivolumab was associated with overall survival rates of 41-42% at 3 years and with an overall survival rate of 35% at 4 and 5 years, suggesting a stable plateau over time and a significant proportion of advanced melanoma patients potentially cured.
authors: Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori.
authors: Michele
authors: M
authors: Del Vecchio
mesh_terms: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma; D000077594:Nivolumab; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab